(VIANEWS) - Tenaris S.A. (TS), Catalyst Pharmaceuticals (CPRX), Arcelor Mittal (MT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Tenaris S.A. (TS)
60.3% sales growth and 12.07% return on equity
Tenaris S.A. produces and sells seamless steel tubes through its subsidiaries. It also provides services related to the oil and natural gas industry and other industrial uses.
Tenaris S.A.'s sales growth this year is expected to be 60.7% and 7.1% for next year.
Year-on-year quarterly revenue growth grew by 100.3%, now sitting on 7.71B for the twelve trailing months.
Volume
Today's last reported volume for Tenaris S.A. is 1827600 which is 32.52% below its average volume of 2708690.
Tenaris S.A.'s sales growth for the next quarter is 60.3%. The company's growth estimates for the current quarter and the next is 68% and 57.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.07%.
Volatility
Tenaris S.A.'s last day, last week, and last month's current intraday variation average was 0.71%, 1.42%, and 1.88%, respectively.
Tenaris S.A.'s highest amplitude of average volatility was 2.27% (day), 2.78% (last week), and 3.26% (last month), respectively.
Tenaris S.A.'s Stock Yearly Top and Bottom Value
Tenaris S.A.'s stock is valued at $34.14 at 01:22 EST, under its 52-week high of $34.76 and way higher than its 52-week low of $18.80.
Tenaris S.A.'s Moving Average
Tenaris S.A.'s worth is above its 50-day moving average of $31.47 and way higher than its 200-day moving average of $25.01.2. Catalyst Pharmaceuticals (CPRX)
53.5% sales growth and 20.98% return on equity
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical firm that focuses on the development and commercialization of therapies for individuals with neurological and rare neuromuscular diseases.
Catalyst Pharmaceuticals's sales growth this year is anticipated to be 42.1% and 15.8% for next year.
Year-on-year quarterly revenue growth grew by 23.5%, now sitting on 140.83M for the twelve trailing months.
Volume
Today's last reported volume for Catalyst Pharmaceuticals is 768975 which is 33.15% below its average volume of 1150400.
Catalyst Pharmaceuticals's sales growth for the next quarter is 53.5%. The company's growth estimates for the current quarter and the next is 54.5% and 90%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.98%.
Volatility
Catalyst Pharmaceuticals's last day, last week, and last month's current intraday variation average was 2.04%, 2.83%, and 2.41%, respectively.
Catalyst Pharmaceuticals's highest amplitude of average volatility was 3.04% (day), 4.43% (last week), and 4.59% (last month), respectively.
Catalyst Pharmaceuticals's Stock Yearly Top and Bottom Value
Catalyst Pharmaceuticals's stock is valued at $6.39 at 01:22 EST, way under its 52-week high of $8.65 and way higher than its 52-week low of $4.81.
Catalyst Pharmaceuticals's Moving Average
Catalyst Pharmaceuticals's worth is way below its 50-day moving average of $7.53 and below its 200-day moving average of $6.78.3. Arcelor Mittal (MT)
47.1% sales growth and 18.21% return on equity
ArcelorMittal and its affiliates own and operate steel mining and manufacturing facilities across Europe, North America, Asia and Africa.
Arcelor Mittal's sales growth this year is expected to be 46.1% and a negative 11.5% for next year.
Year-on-year quarterly revenue growth grew by 76.2%, now sitting on 62.99B for the twelve trailing months.
Volume
Today's last reported volume for Arcelor Mittal is 3073600 which is 23.56% below its average volume of 4021060.
Arcelor Mittal's sales growth for the next quarter is 47.1%. The company's growth estimates for the present quarter and the next is 2536.8% and 1826.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.21%.
Volatility
Arcelor Mittal's last day, last week, and last month's current intraday variation average was 5.77%, 3.34%, and 3.18%, respectively.
Arcelor Mittal's highest amplitude of average volatility was 2.19% (day), 2.84% (last week), and 2.52% (last month), respectively.
Arcelor Mittal's Stock Yearly Top and Bottom Value
Arcelor Mittal's stock is valued at $26.23 at 01:22 EST, way below its 52-week high of $36.58 and way higher than its 52-week low of $20.50.
Arcelor Mittal's Moving Average
Arcelor Mittal's value is way under its 50-day moving average of $30.75 and way below its 200-day moving average of $30.93.4. iRadimed Corporation (IRMD)
19.8% sales growth and 16.6% return on equity
IRADIMED CORPORATION designs, produces, markets and distributes compatible magnetic resonance imaging (MRI), medical devices and accessories in the United States as well as internationally.
iRadimed Corporation's sales growth this year is anticipated to be 25.9% and 14.5% for next year.
Year-on-year quarterly revenue growth grew by 33.5%, now sitting on 44.9M for the twelve trailing months.
Volume
Today's last reported volume for iRadimed Corporation is 3845 which is 95% below its average volume of 76930.
iRadimed Corporation's sales growth for the next quarter is 19.8%. The company's growth estimates for the present quarter and the next is 64.3% and 8.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.6%.
Volatility
iRadimed Corporation's last day, last week, and last month's current intraday variation average was 3.28%, 2.05%, and 1.92%, respectively.
iRadimed Corporation's highest amplitude of average volatility was 3.82% (day), 3.69% (last week), and 4.14% (last month), respectively.
iRadimed Corporation's Stock Yearly Top and Bottom Value
iRadimed Corporation's stock is valued at $32.99 at 01:22 EST, way under its 52-week high of $55.92 and way higher than its 52-week low of $27.34.
iRadimed Corporation's Moving Average
iRadimed Corporation's worth is way under its 50-day moving average of $37.46 and way below its 200-day moving average of $40.55.5. Credicorp Ltd. (BAP)
14.5% sales growth and 13.99% return on equity
Credicorp Ltd. is a holding company for financial services. It provides a variety of financial, insurance and health products, both in Peru and abroad.
Credicorp Ltd.'s sales growth this year is expected to be 74.7% and a negative 28.1% for next year.
Year-on-year quarterly revenue growth grew by 37.7%, now sitting on 13.07B for the twelve trailing months.
Volume
Today's last reported volume for Credicorp Ltd. is 385623 which is 35.33% below its average volume of 596336.
Credicorp Ltd.'s sales growth is a negative 0% for the present quarter and 14.5% for the next. The company's growth estimates for the current quarter and the next is a negative 0% and 59.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.99%.
Volatility
Credicorp Ltd.'s last day, last week, and last month's current intraday variation average was 1.45%, 0.94%, and 2.56%, respectively.
Credicorp Ltd.'s highest amplitude of average volatility was 3.29% (day), 2.83% (last week), and 4.45% (last month), respectively.
Credicorp Ltd.'s Stock Yearly Top and Bottom Value
Credicorp Ltd.'s stock is valued at $137.63 at 01:22 EST, way under its 52-week high of $182.11 and way higher than its 52-week low of $88.67.
Credicorp Ltd.'s Moving Average
Credicorp Ltd.'s value is under its 50-day moving average of $147.84 and higher than its 200-day moving average of $132.39.6. Globus Medical (GMED)
11.2% sales growth and 9.19% return on equity
Globus Medical, Inc., is a medical device firm that focuses on developing and marketing implants to treat patients suffering from musculoskeletal problems.
Globus Medical's sales growth this year is expected to be 7.1% and 10.2% for next year.
Year-on-year quarterly revenue growth grew by 7.1%, now sitting on 958.1M for the twelve trailing months.
Volume
Today's last reported volume for Globus Medical is 363902 which is 56.78% below its average volume of 842028.
Globus Medical's sales growth for the next quarter is 11.2%. The company's growth estimates for the present quarter and the next is a negative 5.4% and 6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.19%.
Volatility
Globus Medical's last day, last week, and last month's current intraday variation average was 3.59%, 1.79%, and 2.01%, respectively.
Globus Medical's highest amplitude of average volatility was 4.87% (day), 2.88% (last week), and 3.74% (last month), respectively.
Globus Medical's Stock Yearly Top and Bottom Value
Globus Medical's stock is valued at $66.59 at 01:22 EST, way under its 52-week high of $84.23 and way higher than its 52-week low of $57.21.
Globus Medical's Moving Average
Globus Medical's worth is under its 50-day moving average of $69.56 and under its 200-day moving average of $72.10.7. TrueBlue (TBI)
9.6% sales growth and 14.29% return on equity
TrueBlue's sales growth this year is expected to be 10.2% and 6% for next year.
Year-on-year quarterly revenue growth grew by 20.2%, now sitting on 2.27B for the twelve trailing months.
Volume
Today's last reported volume for TrueBlue is 466504 which is 97.73% above its average volume of 235919.
TrueBlue's sales growth is a negative 0% for the current quarter and 9.6% for the next. The company's growth estimates for the ongoing quarter and the next is 14.9% and 18.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.29%.
Volatility
TrueBlue's last day, last week, and last month's current intraday variation average was 11.34%, 7.27%, and 3.60%, respectively.
TrueBlue's highest amplitude of average volatility was 12.52% (day), 8.67% (last week), and 4.57% (last month), respectively.
TrueBlue's Stock Yearly Top and Bottom Value
TrueBlue's stock is valued at $16.44 at 01:22 EST, way under its 52-week low of $19.20.
TrueBlue's Moving Average
TrueBlue's worth is way under its 50-day moving average of $25.13 and way below its 200-day moving average of $27.13.Previous days news about TrueBlue(TBI)
- Trueblue stock falls after CEO resigns following investigation into conduct. According to MarketWatch on Wednesday, 15 June, "Shares of TrueBlue Inc. dropped 1.4% in morning trading Wednesday, after the staffing services company disclosed that Chief Executive Patrick Beharelle resigned after has lost 20.6%."